The effect of dietetic counseling combined with digital tools intervention on hemodynamic markers in Greek adults: The GATEKEEPER Study.

Nutr Metab Cardiovasc DisMay 15, 2026 (epub)
Clinical ResearchCardiologyEndocrinology

Rafaela Makri, Iliana Evangelou, Maria Vlachava et al.

✦ AI-curated · Sources linked

In 30 seconds

The GATEKEEPER Study, a randomized controlled trial, assessed the impact of dietetic counseling combined with digital tools on hemodynamic markers in 954 Greek adults aged ≥55 with cardiometabolic risk. Over 3 months, all groups showed improvements, with the Platform + Devices group achieving a significant increase in physical activity (94.62 MET-min/week) and a notable reduction in pulse pressure (-3.90 mmHg) compared to Standard Care.

Key findings

  • Waist circumference decreased by -6.29 cm in Standard Care, -4.92 cm in Platform, and -4.69 cm in Platform + Devices.
  • Systolic blood pressure declined by -4.84 to -7.15 mmHg across all groups.
  • The Platform + Devices group had a greater increase in physical activity of 94.62 MET-min/week.
  • Weight loss was associated with lower odds of hypertension (OR 0.4) and greater likelihood of hypertension reversal (OR 3.6).

Why it matters

This study highlights the importance of dietary lifestyle interventions in managing cardiometabolic risk factors, particularly hypertension. While digital tools may enhance engagement, weight loss remains a critical factor in improving hemodynamic outcomes.

Source

Published in Nutr Metab Cardiovasc Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.